Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1Gastrointestinal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12durvalumab 12Trastuzumab 12Lenalidomide 12daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has announcements × Standard of Care × Clear all
NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT03575351 2025-08-03

TRANSFORM

Celgene

Phase 3 Completed
184 enrolled 30 charts 1 FDA
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Daiichi Sankyo

Phase 2 Completed
233 enrolled 26 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡